Pfizer Korea Defends Reported Market Share Decline of Novarsc

Pfizer Korea defends its position on the reported sharp decline in the domestic market share of Novarsc, by stating that the individual claims on the substitution rates of the original product made by its competing generic makers are not fully representing the market trend as a whole.

The company spokesperson stated that the doctors are continuing to recommend and prescribe Novarsc to the th...